Pharmacokinetics and Safety of a Fully Human Hepatocyte Growth Factor Antibody, AMG 102, in Cynomolgus Monkeys
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
AMG 102, a fully human monoclonal antibody that binds to hepatocyte growth factor (HGF), is a potential cancer therapeutic agent because of its ability to disrupt HGF/c-Met signaling pathways which have been implicated in most tumor types. To support a phase 1 study, the pharmacokinetic and safety profile of AMG 102 was assessed in cynomolgus monkeys.
Materials and Methods
Serum concentration-time data from single-(IV and SC) and repeated-dose (IV) studies of up to 13 weeks were used for pharmacokinetic analysis. Safety was assessed in a single-dose safety pharmacology study with IV doses of 0 (vehicle), 25, 100, or 300 mg/kg and a 4-week toxicity study with once weekly IV doses of 0 (vehicle), 5, 25, or 100 mg/kg.
AMG 102 exhibited linear pharmacokinetics over a 600-fold dose range (0.5 to 300 mg/kg) with a mean terminal half-life of 5.6 days after IV dosing. Clearance and volume of distribution at steady state were 1.22 ml/h and 198.3 ml, respectively. Estimated bioavailability was 72% for SC administration. Antibody response to AMG 102 was observed in a small percentage of monkeys. No treatment-related cardiovascular, respiratory, or CNS changes were observed. Administration of AMG 102 for 4 weeks was well tolerated at doses up to 100 mg/kg. Potential treatment-related effects were limited to minimal/moderate gastric mucosa hemorrhage in the mid- and high-dose groups.
The nonclinical pharmacokinetic and safety profile of AMG 102 effectively supports clinical investigation.
- C. Birchmeier, W. Birchmeier, E. Gherardi, and G. F. Vande Woude. Met, metastasis, motility and more. Nat. Rev., Mol. Cell Biol. 4:915–925 (2003). CrossRef
- L. Trusolino, and P. M. Comoglio. Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat. Rev., Cancer. 2:289–300 (2002). CrossRef
- A. Danilkovitch-Miagkova, and B. Zbar. Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J. Clin. Invest. 109:863–867 (2002). CrossRef
- G. Maulik, A. Shrikhande, T. Kijima, P. C. Ma, P. T. Morrison, and R. Salgia. Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev. 13:41–59 (2002). CrossRef
- L. Schmidt, F. M. Duh, F. Chen, T. Kishida, G. Glenn, P. Choyke, S. W. Scherer, Z. Zhuang, I. Lubensky, M. Dean, R. Allikmets, A. Chidambaram, U. R. Bergerheim, J. T. Feltis, C. Casadevall, A. Zamarron, M. Bernues, S. Richard, C. J. Lips, M. M. Walther, L. C. Tsui, L. Geil, M. L. Orcutt, T. Stackhouse, J. Lipan, L. Slife, H. Brauch, J. Decker, G. Niehans, M. D. Hughson, H. Moch, S. Storkel, M. I. Lerman, W. M. Linehan, and B. Zbar. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat. Genet. 16:68–73 (1997). CrossRef
- P. C. Ma, R. Jagadeeswaran, S. Jagadeesh, M. S. Tretiakova, V. Nallasura, E. A. Fox, M. Hansen, E. Schaefer, K. Naoki, A. Lader, W. Richards, D. Sugarbaker, A. N. Husain, J. G. Christensen, and R. Salgia. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res. 65:1479–1488 (2005). CrossRef
- T. Mukohara, G. Civiello, I. J. Davis, M. L. Taffaro, J. Christensen, D. E. Fisher, B. E. Johnson, and P. A. Janne. Inhibition of the met receptor in mesothelioma. Clin. Cancer Res. 11:8122–8130 (2005). CrossRef
- D. Forbs, S. Thiel, M. C. Stella, A. Sturzebecher, A. Schweinitz, T. Steinmetzer, J. Sturzebecher, and K. Uhland. In vitro inhibition of matriptase prevents invasive growth of cell lines of prostate and colon carcinoma. Int. J. Oncol. 27:1061–1070 (2005).
- T. Burgess, A. Coxon, S. Meyer, J. Sun, K. Rex, T. Tsuruda, Q. Chen, S. Y. Ho, L. Li, S. Kaufman, K. McDorman, R. C. Cattley, J. Sun, G. Elliott, K. Zhang, X. Feng, X. C. Jia, L. Green, R. Radinsky, and R. Kendall. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c- Met-dependent human tumors. Cancer Res. 66:1721–1729 (2006). CrossRef
- S. L. Beal, and L. B. Sheiner. NONMEM Users Guide—Part I Users Basic Guide, NONMEM Project Group, UCSF, San Francisco, CA, 1989.
- H. G. Boxenbaum, S. Riegelman, and R. M. Elashoff. Statistical estimations in pharmacokinetics.J. Pharmacokinet. Biopharm. 2:123–148 (1974). CrossRef
- B. Davies, and T. Morris. Physiological parameters in laboratory animals and humans. Pharm. Res. 10:1093–1095 (1993). CrossRef
- E. D. Lobo, R. J. Hansen, and J. P. Balthasar. Antibody pharmacokinetics and pharmacodynamics. J. Pharm. Sci. 93:2645–2668 (2004). CrossRef
- W. G. Jiang, T. A. Martin, C. Parr, G. Davies, K. Matsumoto, and T. Nakamura. Hepatocyte growth factor, its receptor, and their potential value in cancer therapies. Crit. Rev. Oncol./Hematol. 53:35–69 (2005). CrossRef
- G. F. Vande Woude, M. Jeffers, J. Cortner, G. Alvord, I. Tsarfaty, and J. Resau. Met-HGF/SF: tumorigenesis, invasion and metastatis. Ciba Found Symp. 212:119–130 discussion 130–132, 148–154 (1997).
- T. Burgess, J. Sun, S. Meyer, J. Sun, G. Elliott, Q. Chen, S.Y. Ho, R. Jacobsen, H. Kim, R. Deshpande, F. Martin, T. Tsuruda, K. Zhang, M. Haniu, A. Coxon, and R. Kendall. Characterization of fully human monoclonal antibodies to human hepatocyte growth factor, presented as a “Late Breaking” Abstract #288 at the AACR Annual Meeting, Washington, DC, 2006.
- Pharmacokinetics and Safety of a Fully Human Hepatocyte Growth Factor Antibody, AMG 102, in Cynomolgus Monkeys
Volume 24, Issue 10 , pp 1910-1918
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- anti-HGF antibody
- hepatocyte growth factor
- tyrosine kinase
- Industry Sectors
- Author Affiliations
- 1. Department of Pharmacokinetics and Metabolism, Amgen Inc., Thousand Oaks, California, 91320, USA
- 4. Amgen Inc., One Amgen Center Drive, Thousand Oaks, California, 91320, USA
- 2. Clinical Immunology, Amgen Inc., Thousand Oaks, California, 91320, USA
- 3. Comparative Biology and Safety Sciences, Amgen Inc., Thousand Oaks, California, 91320, USA